PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, UK.\', \'Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.\', \'Early Oncology, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.\', \'R&D IT, AstraZeneca, Cambridge, UK.\', \'Biopharmaceutical Development, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.\', \'Early Oncology, Oncology R&D, AstraZeneca, Cambridge, UK.\', \'Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.\', \'Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, UK.\', \'Global Medical Affairs, Oncology Business Unit, AstraZeneca, Gaithersburg, MD, USA.\', \'Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, UK. mark.fidock@astrazeneca.com.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1038/s41598-021-92070-w
?:hasPublicationType
?:journal
  • Scientific reports
is ?:pmid of
?:pmid
?:pmid
  • 34135391
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.533
?:rankingScore_hIndex
  • 122
?:title
  • A novel automated SARS-CoV-2 saliva PCR test protects a global asymptomatic workforce.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34135391>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34135391>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all